{"id":"glyclazide","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL427216","moleculeType":"Small molecule","molecularWeight":"323.42"},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"_scrapedAt":"2026-03-27T23:47:09.380Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03499808","phase":"PHASE2","title":"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2018-06-06","conditions":"Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea","enrollment":43},{"nctId":"NCT06796660","phase":"EARLY_PHASE1","title":"Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Liu Zhanghong","startDate":"2025-09-01","conditions":"Renal Insufficiency, Chronic","enrollment":70},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT06085703","phase":"NA","title":"Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-04-01","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":24},{"nctId":"NCT01242215","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-09-17","conditions":"Type 2 Diabetes Mellitus","enrollment":243},{"nctId":"NCT00145925","phase":"PHASE3","title":"Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"The George Institute","startDate":"2001-06","conditions":"Diabetes Mellitus, Type 2","enrollment":11140},{"nctId":"NCT06708091","phase":"","title":"Real-world Clinical Effectiveness and Patient Insight Associated With Adding Sodium Glucose Co-transporter 2 Inhibitor to Gliclazide Modified Release","status":"COMPLETED","sponsor":"Servier Affaires Médicales","startDate":"2022-02-15","conditions":"Type 2 Diabetes","enrollment":537},{"nctId":"NCT06704802","phase":"","title":"Observational Cohort Study Evaluating the Effectiveness of an Education Program (NGAYDAUTIEN) in Combination With Gliclazide MR in the Management of Uncontrolled Type 2 Diabetic Patients.","status":"COMPLETED","sponsor":"Servier Affaires Médicales","startDate":"2022-11-04","conditions":"Type 2 Diabetes","enrollment":678},{"nctId":"NCT06613854","phase":"PHASE4","title":"Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2024-10-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":90},{"nctId":"NCT06613750","phase":"PHASE4","title":"Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity","status":"COMPLETED","sponsor":"Zhibin Xu","startDate":"2024-06-01","conditions":"Type 2 Diabetes Mellitus, Glucotoxicity","enrollment":129},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT06222476","phase":"NA","title":"Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.","status":"NOT_YET_RECRUITING","sponsor":"Yan Bi","startDate":"2024-02-20","conditions":"Diabetic Nephropathy Type 2","enrollment":106},{"nctId":"NCT06217887","phase":"NA","title":"Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2020-05-10","conditions":"Type 2 Diabetes Mellitus, Cognitive Function Abnormal","enrollment":58},{"nctId":"NCT03076112","phase":"PHASE3","title":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2017-04-25","conditions":"Type 2 Diabetes Mellitus","enrollment":170},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1147},{"nctId":"NCT03246828","phase":"NA","title":"Glucagon in MODY (Maturity Onset Diabetes of the Young)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2017-07-03","conditions":"MODY1, MODY3","enrollment":10},{"nctId":"NCT03433248","phase":"PHASE4","title":"Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES","status":"UNKNOWN","sponsor":"M.H.H. Kramer","startDate":"2017-11-09","conditions":"Type2 Diabetes","enrollment":66},{"nctId":"NCT04198948","phase":"PHASE1","title":"Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers","status":"COMPLETED","sponsor":"University of Sarajevo","startDate":"2019-03-04","conditions":"Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT04192292","phase":"NA","title":"Study of Sulphonylurea Synergy With DPP4 Inhibitors","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2019-10-08","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT03819790","phase":"PHASE4","title":"The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":119},{"nctId":"NCT00102466","phase":"PHASE3","title":"Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1007},{"nctId":"NCT02682563","phase":"PHASE4","title":"Renoprotective Effects of Dapagliflozin in Type 2 Diabetes","status":"COMPLETED","sponsor":"M.H.H. Kramer","startDate":"2016-02","conditions":"Diabetes Mellitus, Type 2, Diabetic Nephropathies","enrollment":44},{"nctId":"NCT04443777","phase":"PHASE4","title":"Analysis of Ergogenic Potential and Risks Associated With Acute and Chronic Use of Sulphonylureas on Physical Exercise","status":"UNKNOWN","sponsor":"Instituto de Cardiologia do Rio Grande do Sul","startDate":"2020-06-01","conditions":"Resistance Training, Sport Performance, Muscle Recovery","enrollment":44},{"nctId":"NCT04132934","phase":"","title":"Observational Study of Effectiveness and Tolerability of Gliclazide MR 60mg in Diabetic Patients Fasting During RAMADAN","status":"COMPLETED","sponsor":"Servier Affaires Médicales","startDate":"2019-03-11","conditions":"Type 2 Diabetes","enrollment":1200},{"nctId":"NCT01991197","phase":"PHASE2","title":"Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2014-04","conditions":"Psoriasis, Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT00736515","phase":"PHASE4","title":"Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes","status":"COMPLETED","sponsor":"Servier (Tianjin) Pharmaceutical Co. LTD.","startDate":"2008-10","conditions":"Type 2 Diabetes","enrollment":160},{"nctId":"NCT02925559","phase":"PHASE4","title":"Effect of Anti-diabetic Drugs on Glycemic Variability","status":"COMPLETED","sponsor":"Centro de Diabetes Curitiba Ltda","startDate":"2016-10","conditions":"Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT03705195","phase":"NA","title":"Study of Sulphonylurea Synergy With Incretins","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2018-08-03","conditions":"Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT03804411","phase":"PHASE4","title":"Prognostic Predictors of Response to Hypoglycemic Therapy","status":"UNKNOWN","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2017-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":800},{"nctId":"NCT02694263","phase":"PHASE4","title":"Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2016-07","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT03467945","phase":"PHASE1","title":"Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-02-16","conditions":"Healthy","enrollment":40},{"nctId":"NCT03467971","phase":"PHASE1","title":"A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-03-06","conditions":"Healthy","enrollment":21},{"nctId":"NCT02610088","phase":"PHASE4","title":"Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-11","conditions":"Diabetes","enrollment":32},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT03313661","phase":"PHASE3","title":"Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2017-10-14","conditions":"Diabetes","enrollment":60},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT03196154","phase":"","title":"Association Between Insulin Resistance and Beta Cell Function With HbA1C in Diabetics","status":"COMPLETED","sponsor":"Clinical Research Centre, Malaysia","startDate":"2017-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":255},{"nctId":"NCT01847144","phase":"PHASE4","title":"MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2013-04","conditions":"Type 2 Diabetes","enrollment":143},{"nctId":"NCT00738088","phase":"PHASE4","title":"Variation in Sulphonylurea Response in Type 2 Diabetes","status":"TERMINATED","sponsor":"NHS Tayside","startDate":"2007-06","conditions":"Diabetes Mellitus, Type 2","enrollment":14},{"nctId":"NCT02092597","phase":"PHASE4","title":"Safety Evaluation of Adverse Reactions in Diabetes","status":"COMPLETED","sponsor":"Charles University, Czech Republic","startDate":"2013-10","conditions":"Type 2 Diabetes Mellitus","enrollment":42},{"nctId":"NCT00780715","phase":"PHASE4","title":"Response To Oral Agents in Diabetes (ROAD)- Pilot Study","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2008-12","conditions":"Diabetes Mellitus, Type 2","enrollment":29},{"nctId":"NCT01340768","phase":"PHASE3","title":"Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-22","conditions":"Type 2 Diabetes Mellitus","enrollment":870},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT01357135","phase":"","title":"An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-07-15","conditions":"Type 2 Diabetes Mellitus","enrollment":3453},{"nctId":"NCT03125694","phase":"PHASE3","title":"Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-02-01","conditions":"Uncontrolled Type 2 Diabetes Mellitus","enrollment":250},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":"Diabetes Mellitus, Type 2","enrollment":4447},{"nctId":"NCT03068065","phase":"PHASE4","title":"Antidiabetic Effects on Intrahepatic Fat","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2014-05","conditions":"Non-Alcoholic Fatty Liver Disease, Type2 Diabetes","enrollment":87},{"nctId":"NCT02980757","phase":"PHASE1","title":"Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets","status":"WITHDRAWN","sponsor":"Disphar International B.V.","startDate":"2014-06","conditions":"Comparative Bioavailability","enrollment":""},{"nctId":"NCT00102388","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1092},{"nctId":"NCT01679899","phase":"PHASE4","title":"Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability","status":"COMPLETED","sponsor":"Centro de Diabetes Curitiba Ltda","startDate":"2012-12","conditions":"Type 2 Diabetes Mellitus, Menopause, Osteoporosis","enrollment":56},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT01944618","phase":"","title":"forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":"Type 2 Diabetes","enrollment":5000},{"nctId":"NCT02201602","phase":"PHASE4","title":"Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study","status":"COMPLETED","sponsor":"Khoo Teck Puat Hospital","startDate":"2014-08","conditions":"Diabetes","enrollment":8},{"nctId":"NCT02643329","phase":"PHASE1","title":"Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations","status":"COMPLETED","sponsor":"Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited","startDate":"2016-01","conditions":"Healthy","enrollment":17},{"nctId":"NCT02777671","phase":"PHASE1","title":"Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-10","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT02587741","phase":"EARLY_PHASE1","title":"Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-07","conditions":"Diabetic Retinopathy","enrollment":600},{"nctId":"NCT00700856","phase":"PHASE4","title":"Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial","status":"UNKNOWN","sponsor":"Italian Society of Diabetology","startDate":"2008-09","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":3371},{"nctId":"NCT01269996","phase":"PHASE4","title":"JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":71},{"nctId":"NCT02526810","phase":"PHASE4","title":"Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-07","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT01584232","phase":"PHASE3","title":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-04","conditions":"Type 2 Diabetes Mellitus","enrollment":361},{"nctId":"NCT01022762","phase":"PHASE4","title":"Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":440},{"nctId":"NCT00949286","phase":"","title":"Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study","status":"COMPLETED","sponsor":"The George Institute","startDate":"2010-01","conditions":"Diabetes Mellitus, Type 2","enrollment":8494},{"nctId":"NCT01195259","phase":"","title":"Malignancy Meta Analysis for BRL49653","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 2","enrollment":1},{"nctId":"NCT01758380","phase":"PHASE4","title":"Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":557},{"nctId":"NCT01963130","phase":"","title":"Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2012-07","conditions":"Drug Mechanism, Drug Usage","enrollment":97},{"nctId":"NCT00506194","phase":"NA","title":"Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT00978263","phase":"NA","title":"Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2009-02","conditions":"Diabetes","enrollment":47},{"nctId":"NCT01771185","phase":"NA","title":"Metabolic Effects of Gastrointestinal Surgery in T2DM","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2012-10","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT00830297","phase":"PHASE2","title":"Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia","status":"COMPLETED","sponsor":"Marcus Saemann","startDate":"2009-01","conditions":"Hyperglycemia","enrollment":50},{"nctId":"NCT01420692","phase":"NA","title":"The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Ankara University","startDate":"2010-06","conditions":"Type 2 Diabetes Mellitus","enrollment":64},{"nctId":"NCT01426737","phase":"PHASE4","title":"The Swiss Glucose Variability Study","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2011-04","conditions":"Type 2 Diabetes","enrollment":50},{"nctId":"NCT00808860","phase":"PHASE1, PHASE2","title":"Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Hanoi Medical University","startDate":"2008-02","conditions":"Type 2 Diabetes","enrollment":25},{"nctId":"NCT01195532","phase":"","title":"An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects","status":"UNKNOWN","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2010-01","conditions":"Hyperglycemia, Diabetes","enrollment":40},{"nctId":"NCT00367055","phase":"PHASE4","title":"Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Type 2 Diabetes Mellitus","enrollment":84},{"nctId":"NCT00347100","phase":"PHASE4","title":"Insulin Glargine in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Diabetes Mellitus, Type 2","enrollment":387},{"nctId":"NCT00147836","phase":"NA","title":"Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2004-09","conditions":"Type 2 Diabetes Mellitus","enrollment":436},{"nctId":"NCT00169624","phase":"PHASE3","title":"Peripheral and Coronary Endothelial Dysfunction In Type 2diabetic Patients- Role of Metformin","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2005-10","conditions":"Coronary and Peripheral Endothelial Dysfunction","enrollment":30},{"nctId":"NCT00464594","phase":"NA","title":"Japan Early Diabetes Intervention Study","status":"UNKNOWN","sponsor":"Japan Early Diabetes Intervention Study Group","startDate":"2007-04","conditions":"Diabetes Mellitus","enrollment":2560},{"nctId":"NCT00225342","phase":"PHASE4","title":"Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina","status":"WITHDRAWN","sponsor":"University of Glasgow","startDate":"","conditions":"Angina Pectoris, Diabetes Mellitus, Type 2","enrollment":60}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"FATIGUE"},{"count":3,"reaction":"WEIGHT DECREASED"},{"count":3,"reaction":"WEIGHT INCREASED"},{"count":2,"reaction":"ANAEMIA"},{"count":2,"reaction":"BLOOD GLUCOSE DECREASED"},{"count":2,"reaction":"BLOOD PRESSURE INCREASED"},{"count":2,"reaction":"DEATH"},{"count":2,"reaction":"DEPRESSION"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"DRUG INEFFECTIVE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":23,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Glyclazide","genericName":"Glyclazide","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}